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Abstract
Historically, treatment of patients with cancer using chemotherapeutic agents has been associated
with debilitating and systemic toxicities, poor bioavailability, and unfavorable pharmacokinetics.
Nanotechnology-based drug delivery systems, on the other hand, can specifically target cancer
cells while avoiding their healthy neighbors, avoid rapid clearance from the body, and be
administered without toxic solvents. They hold immense potential in addressing all of these issues
which has hampered further development of chemotherapeutics. Furthermore, such drug delivery
systems will lead to cancer therapeutic modalities which are not only less toxic to the patient but
also significantly more efficacious. In addition to established therapeutic modes of action,
nanomaterials are opening up entirely new modalities of cancer therapy, such as photodynamic
and hyperthermia treatments. Furthermore, nanoparticle carriers are also capable of addressing
several drug delivery problems which could not be effectively solved in the past and include
overcoming formulation issues, multi-drug-resistance phenomenon and penetrating cellular
barriers that may limit device accessibility to intended targets such as the blood-brain-barrier. The
challenges in optimizing design of nanoparticles tailored to specific tumor indications still remain;
however, it is clear that nanoscale devices carry a significant promise towards new ways of
diagnosing and treating cancer. This review focuses on future prospects of using nanotechnology
in cancer applications and discusses practices and methodologies used in the development and
translation of nanotechnology-based therapeutics.
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Defining Oncology Applications for Nanotechnology Constructs
Moving a prospective new drug to the clinic is an arduous task. Despite decades of
experience and well-defined best practices for evaluating small molecules as drug
candidates, only one of every 5,000 to 10,000 prospective formulations reaches FDA
approval and only 5% of oncology drugs entering Phase I clinical trials are approved [1].
Recently, chemists, pharmaceutical scientists, biologists, biomedical engineers and
oncologists have turned to nanotechnology in their quest for innovation and improvement of
the success rate in drug development. Nanotechnology is defined by the National
Nanotechnology Initiative (http://www.nano.gov) as research and technology development
at the atomic, molecular or macromolecular scale leading to the controlled creation and use
of structures, devices and systems with a length scale of approximately 100 nanometers
(Figure 1). Examples of nanoparticle platforms are included in Figures 1 and 2. The multi-
functional constructs based on novel nanomaterials can be delivered directly to the tumor
site and eradicate cancer cells selectively. An appropriate nano-construct design allows for
improved drug efficacy at lower doses as compared to the small molecule drug treatment,
wider therapeutic window, and lower side effects. In addition to established therapeutic
modes of action, nanomaterials are opening up entirely new modalities of cancer therapy,
such as photodynamic and hyperthermia treatments. Furthermore, nanoparticle carriers are
also capable of addressing several drug delivery problems which could not be effectively
solved in the past and include overcoming multi-drug-resistance phenomenon and
penetrating cellular barriers that may limit device accessibility to intended targets, blood-
brain-barrier, among others. PEGylated- liposomal doxorubicin (Doxil®, Caelyx®),
liposomal daunorubicin (DaunoXome®), liposomal cytarabine (DepoCyt®), and paclitaxel
albumin-bound particles (Abraxane®) are the only members of this relatively new class of
agents that are approved in the United States (US)[2-7].
The challenges in optimizing design of nanoparticles tailored to specific tumor indications
still remain; however, it is clear that nanoscale devices carry significant promise towards
new ways of diagnosing and treating cancer. This review focuses on future prospects of
using nanotechnology in cancer applications and discusses practices and methodologies used
in the development and translation of nanotechnology-based therapeutics.
Design Trends for a Successful In Vivo Carrier
General Concepts
The therapeutic effects of many anti-cancer drugs and the outcome of anti-cancer therapies
could be significantly improved if: 1) delivery of the drug occurs specifically to tumors
(cancer cells) or preferably inside specific organelles in cells and 2) reduction of drug toxic
side-effects is achieved. In the case of poorly soluble drug candidates the solubility/
bioavailability problem could also be overcome. Various pharmaceutical nanocarriers (e.g.,
liposomes, polymeric micelles, and polymeric nanoparticles) have been used in preparing
novel dosage formulations with good bioavailability and specific drug delivery to tumors.
Zeta potential, size, cationic surface charge and solubility are factors that affect the
biocompatibility of these nanocarriers (Figure 3). These factors influence the cytotoxicity
(surface reactivity), clearance process (renal or biliary), MPS (mononuclear phagocyte
system)/RES (reticuloendothelial system) recognition and EPR (enhanced permeability and
retention) effect.
Multi-functional nanomedicines which are being developed can combine not only different
biological properties (e.g., increased circulation time in blood, ability to accumulate in
tumors via the enhanced permeability and retention effect, and stimulus-sensitivity), but also
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carry a combination of several drugs and diagnostic labels/markers [8]. Targeted
nanosystems which have a capability of targeting specifically cell surfaces or intracellular
components and as such contribute to enhanced accumulation of the drug in tumor are also
emerging [9]. Currently, lipid-based nanomedicines (such as liposomes, lipid-core
polymeric micelles, solid lipid nanoparticles) have gained increased interest due to their
good biological compatibility, easy control over their composition and properties, and
suitability for scale-up to large scale production at reasonable costs [10].
Active Targeting with Ligands and Antibodies
Nearly all cancer nanomedicines utilize some aspect of targeting. Most rely solely upon
“passive” targeting, also known as the enhanced permeability and retention (EPR) effect,
which allows for the extravasation of nanoparticles from the circulation via abnormal
fenestrations in tumor vasculature.
“Active” targeting of nanomedicines provides the additional targeting mechanism of
receptor-mediated binding of nanoparticles to surface receptors expressed on tumor cells or
blood vessels such as ανβ3-integrins [11], folic acid [12], and prostate specific membrane
antigen, also known as PSMA [13]. Research has been conducted on several targeting
ligands, including antibodies, aptamers, peptides and small molecules. Studying transferrin-
targeted nanoparticles, the Davis group at the California Institute for Technology
demonstrated that actively targeted nanoparticles deliver a higher payload to cancer cells
than their passively targeted counterparts [14].
A successful, actively-targeted nanomedicine requires a delicate balance of ligand content
and surface exposure that minimizes immunological recognition and clearance to provide
sufficient nanoparticle circulation time to reach the target cells, while achieving appropriate
binding affinity to the surface receptors expressed on tumor cells or blood vessels. The
presence of multiple targeting ligands per nanoparticle yields a binding affinity stronger than
for the ligand alone, thus enhancing the ligand-receptor binding interaction for the
nanoparticles.
The Langer group at MIT and Farokhzad group at Harvard University demonstrated the
importance of this balance with their aptamer-functionalized, actively-targeted PLGA-PEG
nanoparticles where 5% aptamer surface coverage was ideal for optimal tumor accumulation
[13]. These fundamental findings have been advanced by BIND Biosciences, replacing the
aptamer with a small molecule targeting ligand better suited for pharmaceutical
development, with their PSMA-targeted docetaxel (BIND-014) in a Phase 1 clinical study
for a range of solid tumor cancers (ClinicalTrials.gov Identifier: NCT01300533). The
efficacy of BIND-014 PSMA-targeted docetaxel nanoparticles in PSMA-expressing human
LNCaP prostate cancer xenograft mouse model is presented in Figure 4.
Design Trends for Nanoparticle Intended for Delivery of Special Agents or Distinct
Indications: Highly toxic agents
Since many anti-cancer drugs are highly toxic, it is very desirable to develop nanomedicines
which limit their toxicity at tumor sites with a minimal toxicity towards normal tissues.
Ideally, drugs should be developed which possess toxicity only against diseased or mutated
cells. For example, some inhibitors of poly(ADP-ribose) are highly toxic only against cell
lines exhibiting certain cancer-associated mutations and do not affect cells without such
mutations [15]. However, the development of such drugs with mechanism-based selectivity
is in its infancy. Approaches that are more developed are associated with the specific
targeting of drug-loaded nanoparticles to tumor cells or providing controlled or on-demand
drug delivery. The paradox of targeted delivery is that even with effective targeting, the
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majority of the administered dose ends up in normal tissues throughout the body resulting in
pronounced non-specific off-target toxicity. If targeting efficiency could be increased such
that as little as 3% of the injected dose reaches the tumor site, this would allow for the
dramatic decrease in the total administered dose, thus sharply diminishing the toxic effect to
normal tissues and still providing more drug in the tumor than after “traditional”
administration. Thus, the high cytotoxicity of many anti-cancer drugs can be predominantly
localized only in the tumor. On-demand drug delivery by mesoporous silica nanoparticles
functionalized with a pH-sensitive nano-valve that only opens in acidifying intracellular
endosomal compartments is an example of a novel type of nanocarrier capable of controlled
drug release [16].
Pharmacologic Characterization and Properties
Pharmacologic Nomenclature
The nomenclature used to describe the pharmacokinetic disposition of carrier-mediated
drugs are termed encapsulated or conjugated (drug within or covalently bound to the
carrier), released (the active-drug released from the carrier), and sum total (encapsulated or
conjugated drug plus released drug) [17, 18]. The released drug has also been called the
legacy drug, regular drug, or warhead [17-19]. The released drug consists of a protein bound
or free drug. The pharmacokinetic disposition of these nanoparticle agents is dependent
upon the carrier and not the parent-drug until the drug is released from the carrier [20]. The
drug that remains encapsulated in nanoparticles or linked to a conjugate or polymer is an
inactive-prodrug and thus the drug must be released from the carrier to be active [17, 21].
Whether the drug needs to be released outside of the cell in the tumor extracellular fluid
(ECF) or within the cell depends on the formulation of the carrier and the mechanism of
release [17, 19, 22]. After the drug is released from the carrier, the pharmacokinetic
disposition of the drug will be the same as after administration of the non-carrier form of the
drug [17, 18]. In certain formulations, there may be unencapsulated drug along with the
encapsulated drug; separation and quantitation of each of these species would help explain
complex pharmacokinetics. Many formulations use a combination of drugs for cancer. In
such cases, the encapsulation/conjugation efficiencies and release profiles of individual
drugs may be different depending on the hydrophobicity/hydrophilicity of the drug and the
formulation platform. For synergy, appropriate concentration of drugs reaching the desired
site of action, such as tumor, is critical for efficacy. As such, performing appropriate
pharmacokinetic studies to understand the individual release profiles and fine tuning the
nanomaterial platform for enhanced efficacy is critically important. Thus, the pharmacology
and pharmacokinetics of these agents are complex and detailed studies must be performed to
evaluate the disposition of the encapsulated or conjugated form of the drug, and the released
active-drug and metabolites in plasma, tumors and tissues [21].
Systemic, Tissue and Tumor Disposition of Nanoparticles
Nanoparticles can alter both the tissue distribution and the rate of clearance of the drug by
making the drug take on the pharmacokinetic characteristics of the carrier [23-25].
Pharmacokinetic parameters of the nanoparticles depend on the physiochemical
characteristics of the nanoparticle, such as size, surface charge, shape, nature and density of
coating, composition, stability, membrane lipid packing (in case of liposomal particles),
steric stabilization, deformability, dose, and route of administration [23]. The primary sites
of accumulation of nanoparticles are the tumor, liver, and spleen compared to non-
nanoparticle formulations [23, 24, 26-30]. The development of PEGylated nanoparticles was
based on the discovery that incorporation of PEG onto the surface of nanoparticles yields
preparations with superior prolonged plasma exposures and tumor delivery compared to
non-PEGylated nanoparticles [23, 26, 27].
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The clearance of nanoparticles has been proposed to occur by uptake of the carrier by the
reticuloendothelial system (RES), which is also called the mononuclear phagocytic system
(MPS) (Figure 5) [23, 27, 31]. The MPS uptake of cationic or hydrophobic nanoparticles
results in their rapid removal from the blood and accumulation in tissues involved in the
MPS, such as the liver and spleen. Uptake by the MPS may result in irreversible
sequestering of the encapsulated drug in the MPS, where it can be degraded. In addition, the
uptake of the nanoparticles by the MPS may result in acute impairment of the MPS and
toxicity. The presence of the negatively charged coating on the outside of the nanoparticles
does not prevent uptake by the MPS, but simply reduces the rate of uptake (Figure 5)
[25-27, 32]. The exact mechanism by which steric stabilization of nanoparticles decreases
the rate of uptake by the MPS is unclear [23, 30, 32].
The development of effective chemotherapeutic agents for the treatment of solid tumors
depends, in part, on the ability of those agents to achieve cytotoxic drug exposure within the
tumor via the EPR effect [33, 34]. In addition, studies suggest that the cells of the MPS may
also play a role in the tumor disposition of liposomal agents and in the sensitivity of the
tumors to liposomal agents [35-37]. Once in the tumor, the non-ligand targeted PEGylated
nanoparticles are localized in the extracellular fluid (ECF) surrounding the tumor cell, but
do not enter the cell [38, 39]. Thus, for the nanoparticles to deliver the active form of the
anti-cancer agent, the drug must be released from the nanoparticle into the ECF and then
diffuse into the cell, or taken up into the cell directly and then released [21]. As a result, the
ability of the nanoparticle to carry the anti-cancer agent to the tumor and release it into the
ECF is equally important factors in determining the antitumor effect of nanoparticle anti-
cancer agents. In general, the kinetics of this local release is unknown as it is difficult to
differentiate between the nanoparticle-encapsulated and released forms of the drug in solid
tissue, although with the development of microdialysis, this is becoming easier [21].
Factors Affecting Pharmacokinetic and Pharmacodynamic Variability in Patients
There is significant interpatient variability in the pharmacokinetic disposition of
nanoparticle and liposomal encapsulated agents in patients [17, 37, 40-42]. It appears that
the pharmacokinetic variability of the carrier formulation of a drug is several-fold higher
compared with the non-nanoparticle formulation of the drug [17, 41, 42]. Thus, there is a
need to identify factors associated with the significant pharmacokinetic variability. Most of
the studies evaluating the factors that affect the pharmacokinetic variability of nanoparticle
agents in patients have involved liposomal agents. The factors associated with altered
pharmacokinetics of PEGylated liposomal agents are age, body composition, gender,
presence of tumors in the liver, and changes in and the function of monocytes in blood
(Figure 5). There is a 2- to 3-fold lower clearance of PEGylated liposomal doxorubicin
(Doxil®) and PEGylated liposomal CKD-602 (S-CKD602) in patients ≥ 60 years of age
compared with patients < 60 years of age [43]. Results also suggest that monocytes in blood
engulf S-CKD602 which causes the release of CKD-602 from the liposome and toxicity to
the monocytes, and that the effects are more prominent in patients < 60 yrs. [44]. Patients
with a lean body composition have an increased plasma exposure of encapsulated drug after
administration of S-CKD602 (P = 0.02) (Figure 4). It has also been reported that women
have a lower clearance of encapsulated drug after administration of PEGylated liposomal
agents compared with men. Population pharmacokinetic studies have reported that patients
with refractory solid tumors that have primary or metastatic tumors in the liver have a higher
clearance of S-CKD602 compared with patients that do not have tumors in their liver [45].
In theory, the presence of tumors in the liver may induce the MPS cells in the liver and thus
increase the sequestering of the liposome in the liver which would lead to an increase in
systemic clearance of encapsulated drug [45].
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Gabizon and colleagues reported that the clearance of Doxil® decreased by approximately
25 to 50% from cycle 1 to 3 (Figure 5) [46]. In addition, La and colleagues reported that this
reduction in clearance of Doxil® from cycle 1 to cycle 3 was associated with a reduction in
pre-cycle monocyte count [47]. These studies suggest that there is a reduction in the
clearance of liposomes over time and thus dose reductions may be needed in subsequent
cycles to minimize the risk of toxicity [46]. Interestingly, repeat dose studies of PEGylated
liposomal doxorubicin in mice and rats did not report accumulation of drug in plasma
suggesting that these preclinical models may not accurately reflect the disposition of
PEGylated liposomal agents after repeated dosing [48, 49]. Thus, there is also a need to
develop better preclinical animal models for pharmacology and toxicology studies of
liposomal and nanoparticle agents.
Future studies need to evaluate the mechanism of clearance of nanoparticle agents and
identify the factors associated with pharmacokinetic and pharmacodynamic variability of
nanoparticle anti-cancer agents in patients and specifically in tumors [30, 40, 50-53]. Future
studies also need to develop phenotypic probes that can be used to predict this variability
and individualize therapy with nanoparticle agents.
Translation of Nano-therapeutics – Perception and Reality
The successful translation of anti-cancer nanomedicines from bench to bedside requires
significant efforts which include the development of reasonably simple, inexpensive and
scalable protocols to prepare such medicines, and control over the biological behavior and
pharmacological properties of these preparations. In general, the real use of nanomedicine as
an essential part of personalized medicine will also require the development of multiple
regulatory guidelines and appropriate training and education [54]. The creation of an
“industrial culture” of making nanomedicines including their standardized testing and
characterization is another challenge. It appears that nanomedicines currently under
development will target the most common cancers, such as breast and prostate cancer [55].
The first generation of anti-cancer nanomedicines is based on their “passive” (EPR-
mediated) delivery into tumors, and drugs (such as Doxil®) and diagnostic agents (such as
SPION (superparamagnetic iron oxide nanoparticles)-based NMR contrast agents) are now
approved and in active clinical trials, respectively [56]. Still, despite a clear understanding
that effective anti-cancer nanomedicines should specifically recognize the disease (diseased
cells), provide an imaging signal from the affected zone, and effectively deliver drugs in this
zone, a clear set of uniform requirements to such preparation is still absent [57]. Despite
receiving significant attention [58], rational design of such systems has yet to suggest clear
guidelines for clinical translation. Another important, but unresolved, issue for the
translation of nanoparticle-based medicines is the role of nanoparticle shape and architecture
in their biological behavior and therapeutic properties [59].
Animal models for Preclinical Evaluations of Nanomedicines
As the translation of nanomedicines into clinical practice is still in the early stages, the
concordance of preclinical and clinical data with regard to pharmacokinetics, toxicology and
efficacy are still unknown. However, the developing paradigms underlying nanoparticle
distribution and biocompatibility offer perspective as to what preclinical models are likely to
have the greatest translational utility. One important determinant of nanoparticle
distribution, is the mononuclear phagocyte system (MPS), previously referred to as
reticuloendothelial system, which is responsible for particle sequestration [60]. It appears
that the primary MPS organ(s) of particle sequestration is species dependent, with more
common laboratory animals (e.g., dog, rat and rabbit) having particle distribution primarily
to Kupffer cells of the liver and splenic macrophages, similar to man [61]. In less commonly
used preclinical species (e.g., goat and pig) distribution of particles to pulmonary
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intravascular macrophage is primarily observed [61]. For example, intravenous injection of
nanoparticulate iron oxide resulted in high pulmonary intravascular uptake (> 85% of dose)
in sheep, calf, pig, goat and cat, while uptake was primarily observed in hepatic Kupffer
cells (> 65% of dose) in monkey, hyrax, hamster, rabbit, guinea pig, rat, mouse and chicken
[62]. This would support the use of the more traditional species for toxicological and
pharmacokinetic evaluation of nanomedicines due to the similar MPS distribution profile.
This correspondence in nanoparticle distribution for common laboratory species and man is
also supported by a recent allometeric analysis of clearance of a PEGylated TNF bound gold
nanoparticle in rat, rabbit and man [63]. Across these species, the TNF clearance-brain-
weight product was found to scale proportional to body weight, as has been found for many
macromolecular therapeutics, and would suggest common mechanisms of nanomedicine
disposition in these species. However, a recent study by Caron and colleagues found that the
clearance of a series of PEGylated liposomal anti-cancer agents did not allometrically scale
from mice, rats, and dogs to patients [64]. Thus, the ability to scale the pharmacokinetic
disposition of nanoparticle agents across species may be nanoparticle and model specific. In
the study by Caron, the physiologic co-factors that produced the best scaling of clearance
across animal models and patients were factors associated with the MPS, such as monocyte
count in blood. Thus, new methods of allometric scaling of nanoparticle agents and the use
of MPS characteristics and function need to be evaluated and developed.
The issue of selective tissue distribution and accumulation of nanoparticles is a concern
[65]. Accumulation of nanoparticles in organs of the MPS, or selectively targeted tissues, is
a common occurrence for nanomedicines. For this reason, repeat-dose tissue distribution
studies may be required to identify such tissues, which may then be subjected to greater
scrutiny in subsequent toxicity studies [65]. Similarly, nanoparticle biopersistance is also a
concern, especially for metals and non-biodegradable polymers, and may necessitate lengthy
toxicology studies to identify potential chronic toxicities.
In addition to general pharmacokinetic evaluation, assessing tumor distribution and efficacy
of oncology nanomedicines in relevant preclinical cancer models is also crucial. One issue
unique to nanomedicine tumor distribution in comparison to small molecules is the
dependency upon long systemic circulation and vascular permeability for uptake into the
interstitial space. Studies have identified nanoparticle properties associated with long
circulation, such as PEGylation and small size, that correlate with increased tumor
concentration maxima and total exposure (area-under-the-time-concentration-curve, AUC)
[66]. However, there have been no systematic studies evaluating the clinical relevance of
vascular permeabilities found in these animal models. Studies have shown that tumor
vascular pore size can be highly variable in animal xenografts, ranging from hundreds of
nanometers to microns [67]. As nanomedicine tumor permeability is at least partially
dependent upon vascular pore size, it is important that the tumor model vasculature resemble
the clinical case [68]. In addition to histological type, tumor vascular permeability has also
been shown to vary depending on site of tumor implantation, with orthotopic brain tumors,
for example, having lower permeability than peripherally implanted tumors [69]. This would
suggest a role for the tumor microenvironment in vascular permeability.
Preliminary studies suggest that some clinical tumors contain ultrastructural features, such
as fenestrations, similar to those found in animals models [70]. However, other human
cancers, such as certain brain tumors, appear to be devoid of these pores [71]. Since the
vascular permeability of human cancers in comparison to animal models have not been
thoroughly evaluated, the selection of animal models most appropriate for specific cancer
types with regard to nanoparticle permeability is difficult. At this time, the same
recommendations for small molecule oncology animal model selection would apply to
nanomedicines. NCI's developmental therapeutics program after analyzing the clinical and
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preclinical data sets of several small molecule chemotherapeutics, found that medicines that
were successful in multiple xenograft models were more likely to succeed in the clinic [72].
Since histological correlations of treatment success between clinical and preclinical cancers
were not observed in most cases, this would suggest that xenograft cancer models are not
predictive of specific cancer activity, but rather activity in general. Together with the
variability in tumor vascular architecture and nanomedicine permeability discussed above,
this would suggest that evaluation of nanomedicines in multiple models is prudent. While
veterinary cancers and transgenic models may be more physiologically relevant than
xenograft/syngeneic models, they often suffer from low availability or prolonged time in
generating tumors. For this reason, xenograft/syngeneic models are the most commonly used
models. Syngeneic models, with intact immune systems, would conceivably be an
improvement over xenograft models in athymic nude or SCID mice, especially for
evaluation of nanomedicines, which are prone to immunological interactions (see below).
Likewise, orthotopically implanted tumors, with relevant microenvironments, may also have
advantages.
Previous reviews have suggested the current regulatory framework for assessing the safety
of small molecules, biologics and devices, is considered sufficient for nanomedicines [65].
While that appears to be true at this time, the choice of the most relevant preclinical models
for toxicological evaluation has yet to be identified. Major toxicological issues commonly
observed with cancer nanomedicines are development of immunological and hematological
complications [73]. As an example, cationic dendrimers have recently been reported to
induce disseminated intravascular coagulation in mice [74]. Anaphylactoid reactions are a
primary concern for translational development of iron oxide nanoparticle MR contrast
agents, which may be related to the polymer coatings used and has resulted in removal of
many from the market [75, 76]. Additionally, endotoxin contamination and associated
immunological complications, such as complement activation and pyrexia, is a common
issue for nanomedicines [77]. For this reason, the use of immunologically sensitive species
such rabbit, in addition to historic models (e.g., rodents and dog) which tend to be less
sensitive, is warranted early in preclinical development to identify these possible concerns.
A meta-analysis comparing study design issues of nanoparticle and small molecule anti-
cancer agents in preclinical models and in phase I clinical trials was performed by Morgan
and colleagues [78]. In this study, the degree of dose escalation from starting dose to MTD,
number of dose levels and time to complete the phase I clinical studies were significantly
greater for nanoparticle agents compared with small molecule drugs. These data suggest that
the standard animal models and cross-species scaling paradigms employed to define the
starting dose in the phase I clinical study for small molecule agents may not be optimal for
nanoparticle agents.
In addition to the suggestions regarding animal model selection made above, proper study
design is very important for evaluation of nanomedicines. Whereas the use of intraperitoneal
administration in place of intravenous administration may have little consequence when
evaluating preclinical efficacy or toxicity of small molecules in rodents, due to the high
tissue permeability of these agents, this is not likely the case for many nanomedicines. Due
to their size, nanomedicines do not freely diffuse across tissue barriers, and for this reason
intraperitoneal administration cannot be thought of as a parenteral route equivalent to
intravenous administration. Indeed, studies have shown substantial differences in
distribution when comparing intraperitoneal and intravenous routes of administration [79].
Thus, it is important to use the intended clinical dosing route when evaluating
nanomedicines. Another issue is the use of proper controls. There have been many examples
of both nanoparticle-dependent toxicities and distribution-related shifts in drug toxicities
[80, 81]. For this reason it is important to include both empty (drug-free) nanoparticles and a
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non-nanoparticle (small molecule) formulation of the drug as controls, in order to identify
toxicities related to the nanoparticle platform and shifts in drug-related toxicity.
Role of Nanotech Characterization Laboratory
The Nanotechnology Characterization Laboratory is part of the Alliance for Nanotechnology
in Cancer at NCI's federally funded research and development center (FFRDC; managed by
SAIC Frederick, Inc.) and is a resource for preclinical development of nanomaterial based
drug delivery and imaging agents that are beyond a proof-of-principle stage of development,
with demonstrated biological efficacy. The facility has been established to accelerate clinical
translation of promising nanotechnology derived formulations. This NCI funded resource,
available to academic investigators, industry collaborators and government labs, is
established by NCI in collaboration with the U.S. Food and Drug Administration (FDA),
and the National Institute of Standards and Technology (NIST). Once a project is approved
through a simple submission and material transfer agreement process, a large scale batch is
obtained from the collaborator for testing at NCL facilities. The lab conducts preclinical
assessment through an established assay cascade that includes thorough physico-chemical
assessment, relevant in vitro studies to investigate biocompatibility and in vivo ADME/tox,
efficacy and imaging studies in rodent models as appropriate. The outcome of the NCL
studies is a client report that is provided to the collaborator to further their concept towards
an investigational new drug (IND) submission or an investigational device exemption [82]
with the FDA.
In addition to the pre-clinical assessment, NCL is actively engaged in standard protocol
development and reference material standards development through collaborations. The
NCL also plays an active role in educational and knowledge sharing efforts to advance the
nanomedicine field. For further information, visit: http://ncl.cancer.gov
Scale-up and Manufacturing Issues
A critical element for successful development and commercialization of any pharmaceutical
product is a scalable, reproducible manufacturing process. Besides typical considerations
and challenges with scale up and commercial manufacture, there are additional challenges
for nanotechnology-based products for treating cancer. Some of the most critical aspects of
the manufacture of cancer nanomedicines include sterility (most will be administered
intravenously), nanoparticle size and polydispersity, encapsulation efficiency, removal of
free drug, and drug release rate. In addition, for actively-targeted cancer nanomedicines that
employ receptor-mediated binding of nanoparticles to tumors, the amount and appropriate
surface exposure of targeting ligand must be addressed.
The most important quality parameter for an injectable product is sterility. Achieving
sterility may be quite difficult since terminal heat sterilization could disrupt nanoparticle
size and polydispersity, negatively impacting trafficking and biodistribution. Also, if
nanoparticle size is much greater than 100 nm and polydispersity is broad, sterile filtration
may not work. This leaves few options, including use of sterile raw materials and aseptic
processing, which is very costly, or gamma irradiation, which many nanoparticle products
also may not withstand.
The removal of unencapsulated drug from nanoparticle drug products is often difficult, yet
free or non-encapsulated drug contamination will compromise both efficacy and safety.
Likewise, if the manufacturing process cannot control the drug release rate from
nanoparticles, performance will be unreliable and potentially unsafe if there is a rapid or
high burst of drug released from the carrier. Finally, actively-targeted nanomedicines require
a well-controlled process providing consistent ligand exposure on nanoparticle surfaces to
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fully benefit from effective nanoparticle binding to yield higher tumor drug concentrations
and/or cellular trafficking.
Interaction with Regulatory Agencies
Pathway to the Clinic: Pre-IND and IND Related Studies
Although the FDA and pharmaceutical industry have developed standards to assess drug and
material biocompatibility, immune reactivity, purity and sterility, the unique properties of
nanomaterials often hamper the execution of these standardized protocols and require
special consideration. Thus, while FDA has criteria for the preclinical data that should be
presented in an IND for small-molecule drugs, there is no standardized set of
characterization methods for engineered nanomaterials. In consideration of the novel
properties and often multi-component nature of nanoparticle-based therapeutics, a rational
characterization strategy is comprised of three elements, namely physicochemical
characterization, in vitro assays and in vivo studies. For the physico-chemical
characterization, one needs to have reproducible synthesis and characterization assays for
batch-to-batch consistency that are predictive of in vivo fate. Although the basic criteria for
the chemistry, manufacture, and control (CMC) section of an IND filing is the same, the
methodologies and instrumentation should be appropriate to the type of nanomaterial being
assessed. Additional physicochemical properties that need to be considered include particle
size, size distribution, polydispersity, surface ligand density, surface area, surface charge,
surface functionality, shape and confirmation, composition, purity and stability.
While the number of properties one needs to assess seem to be daunting, once a set of
characterization assays and tools have been identified that are predictive of components that
cause variation in safety, efficacy and potency profiles, the methodologies can be
standardized to qualify lots for batch-to-batch consistency. Nanomaterial size and surface
characteristics are critical for predictive biodistribution and toxicity. For example, most
nanomaterials have polyethylene glycol (PEG) coating. Differences in polydispersity of the
PEG used and the density of the ligands on the surface of the nanoparticles, will result in
significantly different toxicity profiles. For core-shell nanoparticles, impurities can come
from the core and shell reagents that are used. They need to be appropriately assessed to see
if residual free components are present in the drug product. If so, they need to be quantified
using appropriate methods. Purity in the nanomedicine sense can be affected by the presence
of residual solvents, bound and free components (such as unchelated Gadolinium or free
drug) and finally homogeneity, inhomogeneity and heterogeneity in the ligand distribution
that will have significant biological impact.
Apart from these parameters, one has to measure the stability of the formulations as a
function of time, storage, temperature, pH, light (photo stability), diluent, vehicle,
lyophilization, and centrifugation with appropriate methods that will be predictive of
biological effects. These characterization methodologies become much more challenging for
multifunctional nanomaterials intended for drug delivery and imaging. Some of these
challenges can be addressed during the synthesis, purification and characterization steps in a
multi-step synthetic methodology which would allow for purification of unreacted
components and have controls in place to assure uniformity from multiple lots. For self-
assembly methodologies, such as in the case of liposomes or emulsions, the characterization
for a multi-component system is significantly more challenging. Thus, optimization of the
methodology itself with appropriate controls is critical for their success in translation. In the
case of targeted drug delivery systems, such as those with active targeting ligands that bind
to over expressed receptors on tumor, a bioassay predictive of in vivo behavior is critical to
have as part of the analytical techniques to assure activity.
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In vitro characterization is principally performed to elucidate mechanisms of biological
interaction and toxicity and not strictly to screen for biocompatibility. Nonetheless, these in
vitro studies could be very useful to identify areas requiring attention during execution of in
vivo animal studies. While a host of in vitro studies can be carried out with primary and
transformed tissue culture cells to assess features such as nanoparticle uptake, subcellular
localization, intracellular drug delivery, cytotoxic killing, ROS generation and pro-
inflammatory effects, biocompatibility can also be evaluated ex vivo, using blood or blood
cells to discern effects on coagulation, hemolysis, platelet aggregation, complement
activation and phagocytosis. Many in vitro assays can be used to elucidate potential
problems one might encounter during the in vivo assessment phase. While all in vitro assays
are not predictive of in vivo outcome, a set of relevant in vitro assays may be used to
characterize potential issues with the nanoparticle formulation. Since most rodent animal
models are not predictive of human immunotoxicity, the use of human blood, albeit in an in
vitro setting, would point to potential issues during clinical phase of development and can be
used as a screening tool and to optimize the formulation. An important in vitro analysis is
also checking sterility and endotoxin contamination. Preclinical pharmacology and toxicity
studies in animals should be conducted in the most clinically relevant animal model, as
discussed above.
Regulatory agencies are becoming increasingly stringent regarding characterization of the
particle size distribution (PSD) of nanotechnology-based products. Since the PSD may have
a significant influence on the biodistribution and biological efficacy of the formulation, this
parameter is critical to measure and track. This is not a trivial task and needs to be well
understood in order to generate meaningful and actionable data. A review of particle size
analysis is beyond the scope of this article and the reader is referred to the literature [83].
Summary and Future Directions
Historically, treatment of patients with cancer using chemotherapeutic agents has been
associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable
pharmacokinetics. Nanotechnology-based drug delivery systems which can specifically
target cancer cells while avoiding their healthy neighbors, avoid rapid clearance from the
body, and be administered without toxic solvents hold immense potential in addressing all of
these issues. Such drug delivery systems will lead to cancer therapeutic agents which are not
only less toxic to the patient but also significantly more efficacious.
With Doxil® and Abraxane [84, 85] approved by FDA and several new agents undergoing
clinical trials, there is a growing confidence that nanotechnology-based therapeutics will
become an important addition to currently available treatments. It is possible that initially
these new formulations will have limited use due to their incremental improvement in
performance and high cost. However, emerging research efforts indicate that
nanotechnology can address uniquely serious cancer problems which do not have existing
solutions. For example, effective systemic delivery of siRNA has been demonstrated to date
only using nanoparticle delivery vehicles [86]. Additional host of examples include
reduction or elimination of multi-drug resistance [16, 87, 88], broadening of therapeutic
index of existing drug formulations [89-91], and development of anti-metastatic drugs
[92-96]. Thus, persistent further development of nanoparticle drug delivery technologies
will continue and thus these approaches will eventually become important part of
contemporary cancer care.
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Definition of nanotechnology and examples of nanotechnology platforms used in drug
development. This figure was obtained with permission from McNeil et al, Nanotechnology
for the Biologist. Journal of Leukocyte Biology, Volume 78, pages 585-594, 2005 (Figure 3
of this paper).
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Collage of nanomedical particles and devices developed by members of the NCI Alliance
for Nanotechnology in Cancer. This figure was obtained with permission from Hinkal et al,
Cancer Therapy Through Nanomedicine. IEEE Nanotechnology Magazine, Volume 5(2),
pages 6-12, June 2011 (Figure 1 of this paper).(Photo courtesy of the NCI Alliance for
Nanotechnology in Cancer, Nanotechnology Image Library).
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Nanoparticle biocompatibility trends. The zeta potential, size, and solubility affect the
cytotoxicity (surface reactivity), clearance process (renal or biliary), MPS/RES recognition
and EPR effect. This figure was obtained with permission from McNeil. Nanomedicine and
Nanobiotechnology, Volume 1(3), pages 264–271, May/June 2009 (Figure 3 of this paper).
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Efficacy of BIND-014 PSMA-targeted docetaxel nanoparticles in PSMA-expressing human
LNCaP prostate cancer xenograft mouse model. Passively targeted docetaxel nanoparticles
(PTNP, green) decrease tumor growth rate compared to conventional docetaxel (DTXL,
red). BIND-014 (blue) is identical to PTNP in every way except for PSMA-targeting ligand
on the surface. The additional active PSMA binding by BIND-014 results in tumor
shrinkage of nearly 50%, a vast improvement over DTXL. Mice were treated four times
with five mg/kg of DTXL, PTNP or BIND-014 at four day intervals (i.e., Q4D x 4). This
figure was obtained with permission from Gu F, Zhang L, Teply BA, Mann N, Wang A,
Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-
assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105(7):
2586-91.
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Summary of the clearance of nanoparticle agents via the mononuclear phagocyte system
(MPS). Most of the studies evaluating factors affecting nanoparticle agents have been
performed in patients receiving PEGylated and non-PEGylated liposomal agents and thus
these carrier systems are depicted in the figure. However, in theory these factors may also
affect other nanocarrier systems but need to be evaluated in future studies. Nanoparticle
agents are primarily cleared via the monocytes, macrophages and dendritic cells of the MPS
that are located in the liver, spleen, and blood. In addition, the MPS cells in the lung and
bone marrow also appear to be involved. The tumor delivery of nanoparticle agents is
determined by the EPR effect and potentially MPS in tumors. The factors affecting the PK
and PD of nanoparticle agents in patients and animal models included age, gender, body
composition, tumors in the liver, the dose and regimen, other drugs, type of cancer and prior
therapy.
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